Stockwatch: Managing Down Earnings Expectations
This article was originally published in Scrip
Executive Summary
The first-quarter 2016 earnings season for life science companies is about to get underway and if the previous week's early quarterly earnings reports from US banks were anything to go by, expectations are not high. Indeed, even the normally optimistic investment bank analysts have been prefacing the upcoming earnings season at many companies with a good dose of caution.
You may also be interested in...
Stock Watch: Risk And The Pharmaceutical Discount Rate
In contrast to the SEC’s view that public companies’ regulatory filings give investors all the information needed to make an investment decision, the discount rate used to value a company may not reflect all its risks.
Stock Watch: Pharma Businesses That Leave Consumer Behind
Healthcare conglomerates that divorce consumer, animal health and even generics businesses from their pure-play branded pharmaceutical groups could leave a less diversified and riskier sector in uncertain times. But the advantages are apparent.
Stock Watch: Acadia And Amylyx Trial Failures Were No Shock
The overused phrase ‘pipeline in a product’ translates to ‘disappointment in a product’ when the number of indications in the pipeline contracts towards zero.